FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2026.01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Mercedes Colorado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain. Electronic address: mercedes.colorado@scsalud.es. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Treatment of acute myeloid leukemia (AML) in elderly or medically unfit patients remains challenging. Although low-intensity regimens are now standard, intermediate-intensity approaches may still be relevant in selected clinical scenarios. FLAG-IDA LITE was developed as a reduced-intensity adaptation of fludarabine- and cytarabine-based induction to preserve antileukemic activity while improving tolerability. PATIENTS AND METHODS: We conducted a retrospective analysis of elderly or unfit patients with de novo or secondary AML treated with FLAG-IDA LITE at a single institution between 2006 and 2020. Responses were assessed according to Cheson criteria, and cytogenetic risk was classified using the 2010 Medical Research Council (MRC) criteria. Overall survival (OS) was calculated from day 1 of treatment. RESULTS: Ninety-one patients were included, with a median age of 76 years and a high burden of comorbidities and adverse disease features. Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 52 patients (57%). Thirty-day mortality was 9.8%, mainly due to infectious complications during induction. Median OS for the entire cohort was 7 months. Patients achieving CR/CRi had a significantly prolonged median OS compared with nonresponders (19 vs. 4 months). Adverse-risk cytogenetics were associated with lower response rates and inferior survival. CONCLUSIONS: In conclusion, FLAG-IDA LITE yielded modest overall outcomes in a highly vulnerable AML population but provided meaningful survival benefit in patients achieving remission. These findings support a selective role for intermediate-intensity induction regimens in carefully chosen elderly or unfit patients, particularly when rapid disease control is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain. Electronic address: mercedes.colorado@scsalud.es.
- Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain.
- Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain.
Zitieren
APA
Colorado, M., Bermúdez, M. A., Montes, C., Domínguez-García, J. J., Martín, G., Romon, I., & Ocio, E. M. (2026). FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.01.001
Vancouver
Colorado M, Bermúdez MA, Montes C, Domínguez-García JJ, Martín G, Romon I, et al. FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.01.001
BibTeX
@article{Colorado2026,
author = {Colorado, Mercedes and Bermúdez, Mª Aranzazu and Montes, Carmen and Domínguez-García, Juan José and Martín, Guillermo and Romon, Iñigo and Ocio, Enrique M},
title = {FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.01.001}
}
EUVIMED